Postmortem studies have shown that persistent infectious foci can be found in 80 % of patients succumbing to sepsis in the ICU. The development of septic shock was preceding death in almost all the patients3. The optimal outcome of a treatment for gram-negative sepsis would therefore be both reduced mortality and reduced morbidity. However, no specific medical treatment is currently available.
The Alteco® LPS Adsorber has the capacity to significantly reduce endotoxemia when used in hemoperfusion of patients with gram-negative sepsis. This is beneficial to the patients as it dramatically reduces the effects of gram-negative sepsis, such as cardiorespiratory dysfunction and the release of pro- and anti-inflammatory mediators.
More than 2000 treatments have been carried out worldwide using the Alteco® LPS Adsorber. The clinical reports and published data on the efficacy of the Alteco® LPS Adsorber to remove endotoxin from the blood as well as to improve the cardiorespiratory function in patients suffering from severe gram-negative sepsis and septic shock, are unequivocal4,5.
1. Angus, D.C., et al., 2001. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med, 29/7: 1303‒1310
2. Martin, G.S., et al., 2003. The epidemiology of sepsis in the United States from 1979 through 2000. New Engl J Med, 348/16: 1546‒54
3. Torgersen, C., et al., 2009. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg, 108/6: 1841‒7.
4. Ala-Kokko, T.I., et al., 2011. A New Endotoxin Adsorber in Septic Shock: Observational Case Series. Blood Purif, 32: 303‒309
5. Adamik, B. et al., 2015. Endotoxin Elimination in Patients with Septic Shock: An Observation Study. Arch Immunol. Ther. Exp. (online publ)